It is clear the world of TGF-β contains vast potential and excitement, in the past year alone we have seen great advances, clinical setbacks, and novel insights into the role of TGF-β.

Over the last 12 months, we have seen so many highs and lows, including clinical updates from large pharma such as Novartis, Oncotelic Therapeutics, Sanofi. It is also exciting to see emerging biotechs progressing in this area – from Transcenta’s clearance with the FDA for Ph1 anti-PD-L1/TGFb antibody to Lassen Therapeutics uncloaking $31m for their candidate.

With the vast volume of candidates moving into the clinic, it is vital for this community to reconnect at the 2nd TGF-β for Immuno-Oncology Drug Development Summit, the definitive industry-led meeting to harness the therapeutic potential of this target and supercharge pipeline progression.

Tailored with 31+ senior leaders, the 2022 meeting will return with a fresh speaker line-up and dedicated 2 tracks content for a comprehensive guide on TGF-β in immuno-oncology. Whether you are new to this field or a seasoned expert, this meeting will provide you with the must-know takeaways from biology to translational modeling, from biomarkers to clinical trial design across 3 days.

What’s New?

• 31+ world-class speakers from Scholar Rock, Novartis, Pfizer, Mestag Therapeutics, Takeda, Cue Bio, Genentech, and more
• 2 Dedicated Tracks of exclusive preclinical and clinical case studies and data for your invaluable lessons learned
• A TGF-β Boot Camp Day to provide a comprehensive guide on harnessing the potential of this complex target

To know more visit: https://ter.li/nep8yi